IPO Databook: Nexalin Technology (NXL US) - Oct 2026

• Nexalin Technology, Inc. is a medical device company developing innovative neurostimulation products to address the global mental health epidemic. The company's bioelectronic devices treat anxiety, insomnia, and depression without drugs.
• The company developed Gen-1 CES devices and has Gen-2 SYNC and Gen-3 HALO devices in clinical trials, including an FDA-cleared trial for insomnia.
• The company reported significant net losses and negative cash flows from operations, with substantial doubt about its ability to continue as a going concern.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.